254 followers
RT @NCIPhySci: Investigators @CornellPSOC et al. found that the AKT inhibitor MK-2206 had limited clinical activity in advanced #breastcanc…
RT @NCIPhySci: Investigators @CornellPSOC et al. found that the AKT inhibitor MK-2206 had limited clinical activity in advanced #breastcanc…
Investigators @CornellPSOC et al. found that the AKT inhibitor MK-2206 had limited clinical activity in advanced #breastcancer patients with PIK3CA/AKT1, PTEN mutations, or PTEN loss in a Phase 2 #clinicaltrial @BCRJournal https://t.co/augnXsSluN. https://
A Phase II trial using an AKT inhibitor to treat advanced breast cancer was reported in Breast Cancer Research by Drs. Cantley and Mills of the @SU2C PI3K Dream Team and will inform future trials for AKT inhibitors in breast cancer #bcsm https://t.co/jEf